Otros idiomas Medigen Biotechnology Corp.

Acciones

3176

TW0003176004

Precio de cierre Taipei Exchange Otros sitios de cotización 00:00:00 16/07/2024			Varia. Cinco días.	Varia. 1 de enero.
42,95 ^TWD	-0,69 %		-3,27 %	-4,13 %

04/07	Medigen recibe una carta de aprobación del Ministerio de Sanidad y Bienestar Social en la que se confirma que su unidad de procesamiento celular cumple las Buenas Prácticas Tisulares	CI
06/06	Medigen Biotechnology Corp. anuncia que el Mohw de Taiwán aprueba una nueva versión del proyecto de terapia autóloga con células asesinas naturales en colaboración con el Hospital Wanfang	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Medigen Receives Approval Letter from Ministry of Health and Welfare Confirming Its Cell Processing Unit Is Compliant with Good Tissue Practice	04/07
Medigen Biotechnology Corp. Announces Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang Hospital	06/06
Medigen Biotechnology Corp. and Oncolys BioPharma Enroll First Participant in Investigator-Initiated Phase II Clinical Trial	03/06
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
The Ministry of Health and Welfare Approves Collaborative Autologous Gamma-Delta T Cell Therapy Project by Medigen Biotechnology Corp. and Chi Mei Hospital	29/03
Taiwan MOHW Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by Medigen Biotechnology Corp. and Changhua Christian Hospital	26/03
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer	11/03
Medigen Biotechnology Corp. Applies to the Taiwan Food and Drug Administration for Phase I/Ii Clinical Trial Ofallogeneic Natural Killer Cells (Magicell-NK)	29/02
Medigen Biotechnology Corp. Announces That the Ministry of Health and Welfare Has Approved the Collaborative Autologous Gamma-Delta T Cell Therapy Project by the Company and Changhua Christian Hospital	16/02
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	07/02
The Ministry of Health and Welfare Approves the Collaborative Autologous Gamma-Deltat Cell Therapy Project by Medigen Biotechnology Corp.And Taichung Tzu Chi Hospital	11/01
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11/11
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Medigen Biotechnology Corp.

Acciones

3176

TW0003176004

Otros idiomas

Filtros